Iproteos, a case of success in the workshop ‘New forms of philanthropy and social transformation’ Blog Post

Iproteos´s experience, based at the Parc Cientific de Barcelona-  and Creoentuproyecto, has been one of the three successful cases presented today at the conference ‘Between Public and Private – New philanthropic networks in Catalonia‘. The debate closed the series of open dialogues’ New forms of philanthropy and social transformation”, an initiative co-organized by the Catalan Institute for Public Policy Evaluation (Ivàlua) and the Palau Macaya of “la Obra Social la Caixa”, which aims to analyze the philanthropic activity that takes place in our country and prioritize and focus efforts to address the social needs of today’s world.

Iproteos closes the first ‘crowdfunding’ campaign of the Spanish biotech sector Blog Post

The biotech Iproteos -located at the Parc Cientific de Barcelona- has managed to successfully close an innovative funding campaign based on equity crowdfunding with the aim of raising € 100,000 for the development of a new drug to stop progression and reverse the cognitive deficits associated with schizophrenia: IPR019. The funds raised will allow the biotech -a spin-off from the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) – complete the preclinical non-regulatory stage of the compound to begin clinical trials in 2016.

 

Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain Blog Post

The Catalan biotech Iproteos –based in the Parc Cientific de Barcelona (PCB)– has launched an innovative funding campaign based on equity crowdfunding- through the Creoentuproyecto.com platform– which aims to raise 100,000 € to complete the non-regulatory preclinical stage of its compound IPR019. This compound is one of the 20 drugs in the world that are being developed to slow-down the progression of schizophrenia and revert the cognitive deficits of this condition. Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the transfer of a technology generated at Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona (UB). In addition, the Bosch i Gimpera Foundation (FBG) has given advice on the definition of the business plan and negotiated the technology.

Identifiquen nous gens relacionats amb el risc de fractures i d’osteoporosiTO TRANSLATE >>> Blog Post

Els professors Daniel Grinberg, Susana Balcells i Roser Urreizti, del Departament de Genètica i de l’Institut de Biomedicina de la UB (IBUB) –present al Parc Científic de Barcelona– en col·laboració amb l’Institut de Recerca de l’Hospital del Mar (IMIM), han participat en un estudi internacional per identificar nous gens que influeixen en el risc de desenvolupar osteoporosi i fractures òssies. En la recerca, que han liderat Fernando Rivadeneira i Karol Estrada, del Centre Mèdic Erasme, a Rotterdam (Països Baixos), hi han col·laborat equips científics de 50 centres d’Europa, Amèrica del Nord, Àsia i Austràlia.

A study led by professor Francesc Villarroya, among the best papers of 2011 Blog Post

A scientific study, led by Francesc Villarroya, professor of the Department of Biochemistry and Molecular Biologyand director of the Institute of Biomedicine of the University of Barcelona (IBUB), has been designated by The Journal of Biological Chemistry as one of the best papers published in 2011. The 20 papers that have won Best of 2011 designations were selected from more than 4,000 papers published last year. The Best of 2011 were chosen by The Journal of Biological Chemistry’s editors for their excellence and potential impact on their field.